Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will ...

Medtronic and Recor Medical may have some fresh resolutions for the new year after the Centers for Medicare & Medicaid ...

Ring Therapeutics is calling on Singaporean research agencies to dial into a new collaboration to develop gene therapies for eye diseases and cancer. | Ring Therapeutics is calling on Singaporean ...

Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

The FDA has scuttled Merus’ plans to win a speedy approval for i | The FDA has scuttled Merus’ plans to win a speedy approval ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...